| |
Active patients(BASDAI ≥ 4; n= 38)
|
Inactive patients(BASDAI < 4; n= 17)
|
p value
|
|---|
|
IL-6 (pg/mL)
|
20 (6–545)
|
15 (5–277)
|
0.2
|
|
IFNγ (pg/mL)
|
0.002 (0.002–1.96)
|
0.002 (0.002–0.89)
|
0.7
|
|
BAP (U/L)
|
28 (13–107)
|
30 (15–49)
|
0.3
|
|
Vitamin D (nM)
|
89 (4–266)
|
77 (12–240)
|
0.6
|
|
NTX (nM, bone collagen
equivalent)
|
87 (56–131)
|
81 (52–188)
|
0.7
|
|
TRAP 5 (U/L)
|
3.7 (2.2–5.8)
|
3.9 (2.4–6.6)
|
0.4
|
|
hPTH (pg/mL)
|
46 (44–170)
|
77 (45–130)
|
0.08
|
|
sRANKL (pmol/L)
|
264 (101–956)
|
350 (158–1598)
|
0.2
|
|
OPG (pg/mL)
|
367 (52–1118)
|
274 (71–592)
|
0.004
|
|
sRANKL/OPG
|
0.79 (0.14–4.5)
|
1.16 (0.4–22.6)
|
0.02
|
|
Sclerostin (pmol/L)
|
70 (49–126)
|
75 (48–123)
|
0.7
|
|
sFRP1 (ng/mL)
|
0.15 (0.1–17)
|
0.1 (0.1–0.2)
|
0.5
|
|
DKK1 (pg/mL)
|
93 (26–370)
|
130 (17–771)
|
0.5
|
|
BASRI-hip
|
0 (0–4)
|
0.5 (0–4)
|
0.2
|
|
BASRI-spine
|
5.5 (2–12)
|
7 (2–12)
|
0.3
|
|
BASMI
|
4 (1–9)
|
2.5 (1–9)
|
0.7
|
|
BMD-Lumbar spine (g/cm2)
|
0.9 (0.7–1.4)
|
0.9 (0.7–1.6)
|
0.8
|
|
BMD-Femoral neck (g/cm2)
|
0.7 (0.6–1.1)
|
0.8 (0.5–1)
|
0.9
|
- Data are presented as the median with minimum and maximum values. BASDAI= Bath ankylosing spondylitis disease activity index, IL-6= interleukin 6, IFNγ= interferon-gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5 tartrate-resistant acid phosphatase, hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-related protein 1, DKK1= Dickkopf-related protein 1, BASRI= Bath Ankylosing spondylitis radiologic index, BASMI= Bath ankylosing spondylitis metrology index.
